Drug significantly reduces common cough in IPF patients
Trevi Therapeutics has announced positive topline results from its Phase IIb CORAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF).
The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups at Week 6.
The 108mg BID, 54mg BID and 27mg BID dose groups achieved reductions from baseline of 60.2%, 53.4%, and 47.9%, respectively, compared to a placebo reduction from baseline of 16.9%.
Statistically significant improvements were observed across secondary endpoints at Week 6 in the 108mg BID and 54mg BID dose groups.
“The CORAL trial is the first positive Phase IIb parallel group study for the treatment of chronic cough in patients with IPF, a significant milestone for patients and Trevi,” said Jennifer Good, President and CEO of Trevi Therapeutics. “Chronic cough is one of the most debilitating comorbidities for patients with IPF, impacting an estimated 85% of these patients. There are no approved therapies for chronic cough in this population and with these data, Trevi is one step closer to addressing this unmet need.”
In the trial, a 50% reduction in 24-hour cough frequency at Week 6 vs baseline was seen in 65% of patients on 108mg BID Haduvio, 63% of patients on 54mg BID Haduvio and 60% of patients on 27mg BID Haduvio dose groups, compared to 19% of placebo patients.
“In my patients with IPF, chronic cough is one of the most challenging comorbidities I face clinically,” said Philip Molyneaux, Professor of Pulmonary Medicine at the Royal Brompton Hospital, London. “IPF treatments focus on slowing disease progression but have not shown benefit on chronic cough, which can lead to poor health outcomes and quality of life. I am excited about the CORAL data and the potential continued development of nalbuphine ER for this significant unmet need among IPF patients.”
Diana Turner, Senior Digital Content Editor, DDW
